ISRCTN15367345进行中（未招募）2 期
MELD-ATG: Phase II, dose ranging, efficacy study of anti-thymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes (T1D)
niversitair Ziekenhuis Leuven0 个研究点目标入组 16 人开始时间: 2022年5月11日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 16
研究概览
简要总结
2021 Protocol article in https://pubmed.ncbi.nlm.nih.gov/34876434/ (added 31/01/2022)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Have given written informed consent to participate or have a parent or legal guardian provide informed consent if the subject is under the age of consent (age may vary in different countries; <16 years of age in the UK)
- •2. Age =5 years =25 years at consent
- •3. Have been diagnosed with T1D within 3-9 weeks of planned treatment day 1
- •4. Have random C-peptide levels =200 pmol/l measured at screening, as tested centrally
- •5. Have 1 or more diabetes-related autoantibody (GADA, IA-2A or ZnT8A) present at screening, as tested centrally
- •6. Will be =6 weeks from last live immunisation at planned treatment day 1 and be willing to forgo live vaccines during the trial until 6 months post-treatment
- •7. Be willing to comply with intensive diabetes management
排除标准
- •1. Type 2 diabetes
- •2. Evidence of prior or current tuberculosis (TB) infection
- •3. Clinically significant abnormal full blood count (FBC), renal function or liver function at screening, including:
- •3.1. Immunodeficient or clinically significant chronic leucopenia, neutropenia, lymphopenia or thrombocytopenia at the screening visit, according to local reference ranges
- •3.2. Evidence of liver dysfunction with aspartate aminotransferase (AST) or alanine transaminase (ALT) greater than 3 times the upper limit of normal (ULN), at screening
- •3.3. Evidence of renal dysfunction with creatinine greater than 1.5 times the ULN at screening
- •4. Requiring use of other immunosuppressive or immunomodulation agents, including chronic use of systemic steroids
- •5. Any active chronic infections at screening, or any active acute or chronic infections at baseline or on treatment day, which would contraindicate any additional immunosuppression
- •6. Seropositive for human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection at screening
- •7. Positive for SARS-CoV-2 based on local testing regimen
- •8. Unwilling to use appropriate contraception if sexually active during the trial, from date of written informed consent until completion of the 12-month follow-up visit
- •9. Any history of malignancies, other than skin
- •10. Current or ongoing use of non-insulin pharmaceuticals that affect glycaemic control
- •11. Active participation in another T1D treatment interventional trial in the previous 30 days prior to screening (excluding treatment with insulin)
- •12. Any prior treatment with ATG, abatacept or anti-CD3
- •13. Known allergy to ATG or to similar products
- •14. Any condition, complicating medical issues, or abnormal clinical laboratory results that the investigator judges may adversely affect trial conduct, cause increased risk to the participant, or compromise the trial results
研究者
相似试验
已完成
2 期
MELD-ATG: Phase II, Dose Ranging, Efficacy Study of Anti-thymocyte Globulin (ATG) Within 6 Weeks of Diagnosis of Type 1 Diabetes (T1D)Diabetes Mellitus, Type 1NCT04509791Universitaire Ziekenhuizen KU Leuven114
终止
1 期
A Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG 016 Monotherapy in Patients With Advanced Solid TumorsAdvanced Solid TumorsNCT05010525Shanghai Antengene Corporation Limited8
已完成
1 期
A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)Leukemia, Myeloid, AcuteMyelodysplastic SyndromesNCT03915379Janssen Research & Development, LLC68
终止
1 期
Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.Non Small Cell Lung CancerNCT02335944Novartis Pharmaceuticals177
终止
1 期
Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants.Acute Myeloid LeukaemiaNCT03217838AstraZeneca50